A new treatment option for opioid use disorder has been approved by the FDA: buprenorphine.

Published Date: 26 May 2023

Now, the U. S. For use subcutaneously (under the skin), the Food and Drug Administration has approved the extended-release injection of buprenorphine known as Brixadi.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Advances in "next generation" photoactive cancer therapy

2.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

3.

The American College of Physicians updated its recommendations for colorectal cancer screening.

4.

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma

5.

According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot